

See discussions, stats, and author profiles for this publication at: <https://www.researchgate.net/publication/281485029>

Ameliorating Role Exerted by Al-Hijamah in Autoimmune Diseases: Effect on Serum Autoantibodies and Inflammatory Mediators

Article in *International Journal of Health Sciences* · April 2015

Source: PubMed

CITATIONS

31

READS

1,926

8 authors, including:



Hussam Baghdadi

Taibah University

43 PUBLICATIONS 659 CITATIONS

[SEE PROFILE](#)



Ayman Barghash

Alexandria University

2 PUBLICATIONS 33 CITATIONS

[SEE PROFILE](#)



Manal Nabo

Tokushima University

35 PUBLICATIONS 659 CITATIONS

[SEE PROFILE](#)



Salah Mohamed El Sayed

Sohag University in Egypt, Taibah University in Saudi Arabia

85 PUBLICATIONS 1,389 CITATIONS

[SEE PROFILE](#)

Review article

Ameliorating Role Exerted by Al-Hijamah in Autoimmune Diseases: Effect on Serum Autoantibodies and Inflammatory Mediators

Hussam Baghdadi,⁽¹⁾ Nada Abdel-Aziz,^(2, 3) Nagwa Sayed Ahmed,⁽⁴⁾ Hany Salah Mahmoud,⁽⁵⁾ Ayman Barghash,^(1, 6) Abdullah Nasrat,⁽⁷⁾ Manal Mohamed Helmy Nabo,^(8, 9) Salah Mohamed El Sayed^(1, 4)

Department of Clinical Biochemistry and Molecular Medicine, Taibah Faculty of Medicine, Taibah University, Al-Madinah Al-Munawwarah, Kingdom of Saudi Arabia⁽¹⁾

Department of Medical Microbiology and Immunology, Taibah Faculty of Medicine, Taibah University, Al-Madinah Al-Munawwarah, Kingdom of Saudi Arabia⁽²⁾

Department of Medical Microbiology and Immunology, Sohag Faculty of Medicine, Sohag University, Egypt⁽³⁾

Department of Medical Biochemistry, Sohag Faculty of Medicine, Sohag University, Egypt⁽⁴⁾

World Federation of Alternative and Complementary Medicine, Cairo Regional Headquarter, Cairo, Egypt⁽⁵⁾

Department of Medical Biochemistry, Alexandria Faculty of Medicine, Alexandria University, Egypt⁽⁶⁾

Balaghoun Clinics compound, Jeddah, Kingdom of Saudi Arabia⁽⁷⁾

Department of Pediatrics, Sohag Teaching Hospital, Sohag, Egypt⁽⁸⁾

Division of Pediatric cardiology, Department of Pediatrics, Maternity and Children Hospital, King Abdullah Medical City, Al-Madinah Al-Munawwarah, Kingdom of Saudi Arabia⁽⁹⁾

Abstract

Autoimmune diseases have common properties characterized by abnormal blood chemistry with high serum autoimmune antibodies, and inflammatory mediators. Those causative pathological substances (CPS) cannot be excreted by physiological mechanisms. Current treatments for autoimmune diseases involve steroids, cytotoxic drugs, plasmapheresis and monoclonal antibodies. Wet cupping therapy (WCT) of prophetic medicine is called Al-hijamah that treats numerous diseases having different etiology and pathogenesis via a pressure-dependent and size-dependent non-specific filtration then excretion of CPS causing clearance of blood and interstitial fluids. Al-hijamah clears blood passing through the fenestrated skin capillaries. Medical bases of Al-hijamah were reported in the evidence-based Taibah mechanism (Taibah theory). Al-hijamah was reported to be an excellent treatment for rheumatoid arthritis that improved patients' blood chemistry and induced significant clinical improvement and pharmacological potentiation. Al-hijamah improved the natural immunity and suppressed the pathological immunity through decreasing the serum level of autoantibodies, inflammatory mediators, and serum ferritin (a key player in autoimmunity). Al-hijamah reduced significantly pain severity, number of swollen joints and disease activity with no significant side effects. Main steps of Al-hijamah are skin suction (cupping), scarification (sharatmihjam in Arabic) and second suction (triple S technique) that is better therapeutically than the traditional WCT (double S technique). Whenever an excess noxious substance is to be removed from patients' blood and interstitial fluids, Al-hijamah is indicated. Shartatmihjam is a curative treatment in prophetic teachings according to the prophetic hadeeth: "Cure is in three: in shartatmihjam, oral honey and cauterization. I do not recommend my nation to cauterize". Al-hijamah may have better therapeutic benefits than plasmapheresis. Al-hijamah may be promising in treating autoimmune diseases as a sole treatment or adjuvant treatment.

Key words:

Autoimmune diseases, Al-hijamah, Prophetic medicine, Serum ferritin, Rheumatoid arthritis and Plasmapheresis.

List of abbreviations

CPS	Causative pathological substances
DS-DNA	Double-stranded DNA
IC	Immune complexes
Ig	Immunoglobulin
MHC	Major Histocompatibility Complex
NK cells	Natural killer cells
RA	Rheumatoid arthritis
RBCs	Red blood cells
SLE	Systemic lupus erythematosus
TNF	Tumor necrosis factor
WBCs	White blood cells
WCT	Wet cupping therapy

Correspondence:

Professor Salah Mohamed El Sayed, M.D., Ph.D.

Assistant Professor

Clinical Biochemistry and Molecular Medicine Department

Taibah Faculty of Medicine

Taibah University

Saudi Arabia

Email: salahfazara@yahoo.com, drsalahpediatr@yahoo.com

Introduction

The mere presence of autoantibodies is sufficient to establish the diagnosis of autoimmune diseases, which requires more clinical and additional laboratory evaluation.⁽¹⁻³⁾

In general, B-cell stimulation is dependent upon help gained from T cells. Multiple mechanisms exist to regulate the function of self-recognizing T lymphocytes including peripheral deletion mechanisms, induction of anergy and active suppression of self-reacting lymphocytes. Immunopathology of autoimmune diseases involves participation of autoantibodies, complement activation and disorders related to cell-mediated and humoral immunity.⁽⁴⁾

Autoimmune diseases are characterized by an abnormal blood chemistry in which there are high serum levels of auto-antibodies, immune complexes, inflammatory mediators, inflammatory cytokines, soluble cytokine receptors, prostaglandins and others.⁽⁴⁾ There is no physiological mechanism to clear serum and/or interstitial fluids from these abnormal constituents. Also, there is no pharmacological treatment to restore the normal blood chemistry or homeostasis through excretion of the above-mentioned pathological substances. Current pharmacological treatments of autoimmune diseases may suppress the inflammatory and autoimmune reactions but do not clear patient's serum or interstitial fluids from the above-mentioned causative pathological substances (CPS). Such pharmacological treatments include steroids,⁽⁵⁾ potent anti-inflammatory drugs, cytotoxic drugs,⁽⁶⁾ disease-modifying anti-rheumatic drugs⁽⁷⁾ and monoclonal antibodies directed against target cells or autoimmune antibodies.⁽⁸⁾ Numerous drug side effects are encountered in pharmacological treatments used for treating autoimmune diseases e.g. non-steroidal anti-inflammatory drugs induce gastritis, gastric ulcers and toxicities at high doses, while prolonged steroid therapy causes osteoporosis, hypertension, steroid diabetes, gastric ulcers and steroid dependence.⁽⁵⁾ Cytotoxic drugs have many unavoidable serious side effects, which may necessitate drug discontinuation.^(6, 9)

Non-specific immuno-suppression may help in treatment of all autoimmune disorders, but adverse side-effects (acquired immunodeficiency diseases, cancer and drug

toxicity) can harm the patients rather than benefiting them.^(4, 10)

Autoimmune diseases may be organ specific (e.g. Hashimoto's thyroiditis), a mixture of organ specific and systemic symptoms (e.g. rheumatoid arthritis, RA) or diseases with non-organ specific autoimmune reactivity (e.g. systemic lupus erythematosus, SLE).^(3, 4)

Al-hijamah (cupping therapy of prophetic medicine) is a well-known treatment modality in the Arabic medical literature in Arabic countries as it is a highly recommended treatment in prophetic medicine.⁽¹¹⁻¹²⁾

In this article, we will review here important aspects regarding autoimmune diseases, Al-hijamah as a promising treatment, scientific bases beyond Al-hijamah and therapeutic roles of Al-hijamah in treating autoimmune diseases that may be an adjuvant treatment to current treatment modalities for treating autoimmune diseases.⁽¹²⁾

Immunological tolerance (table 1):

The autoreactive B and T-lymphocytes that are sensitized against self-antigens are key players in the pathogenesis of autoimmunity. Immunological tolerance refers to immunological unresponsiveness towards one's own self antigens. It is also called autotolerance and is regulated through many immunological mechanisms in both B and T lymphocytes that prevent them from attacking self-antigens.⁽¹⁻⁴⁾ Loss of self-tolerance leads to autoimmunity. Mechanisms for tolerance induction include deletion of autoreactive T-lymphocytes (activation-induced cell death), suppression and deletion of autoreactive B-lymphocytes in the bone marrow, lack of T-cell help for B-cell activation, removal of necessary signals for induction of autoreactivity, absence of appropriate major histocompatibility complex (MHC) molecules for antigen presentation and absence of co-stimulatory molecules.^(3-4, 13-14)

Causes of autoimmunity (table 1):

Causes of autoimmunity are wide and diverse. Autoimmunity occurs upon lack of immunological tolerance leading to attack of self-antigens by the own immune system. Autoimmunity has a familial predisposition and is enhanced with infectious microbes producing peptide antigens similar in structure to self-antigens (molecular mimicry), where bacterial peptides cross-react with self-

antigens leading to activation of the immune system.⁽¹⁵⁾

Moreover, drugs, chemicals bacterial infections and viral infections may cause alteration of self-antigens e.g. tissue proteins, which may affect the behavior of the immune system towards these tissue proteins. Infection with streptococci may cause cross-reactivity of the immune system towards self-antigens where an immunological reaction occurs against the protein of the heart valves resulting in the pathogenesis of rheumatic fever.⁽¹⁶⁾ Similar to that is the appearance of new antigens that are similar to tissue antigens by the effect of viral infections or chemical substances⁽¹⁶⁾ leading to self-attack by one's immunological system^(3, 13, 17) e.g. short amino acid sequences in myelin basic protein are identical to sequences in an adenovirus (type-2) protein, while other sequences are homologous to sequences in hepatitis B protein. Altered antigen presentation refers to the presentation of antigens together with MHC by cells not normally expressing MHC.^(4, 18-20) This may participate in induction of autoimmunity.

It is noteworthy that defects in the normal regulation of lymphocyte development and activation e.g. defects predisposing to low regulatory T-helper-2, cytokine production and

lack of induction of apoptosis to autoreactive T-cell clones "bystanders" during normal immunological responses to infection may break the immunological tolerance leading to autoimmunity.^(4, 21)

Etiology of autoimmune diseases includes also genetic defects leading to defects in lymphocyte regulation, loss of stimuli causing apoptosis, development of antigen-related mechanisms and effects of some hormones.⁽²²⁻²³⁾ The ratio of females to males presenting with Hashimoto's thyroiditis is 50:1 and 10:1 in SLE, while the male to female ratio is 9:1 in ankylosing spondylitis.^(3-4, 24)

Superantigen-related mechanisms may cause autoimmunity i.e. superantigens activate entire sets of T cells whose T-cell receptors share a common variable region segment. This occurs typically in the T-cell receptor- β chain leading to sensitization of T cells (table 1).^(9, 25)

Antigen-related mechanisms include molecular mimicry following infection, cross reactivity with microbial antigens, release of previously sequestered antigens (e.g. during surgery, crystalline lens becomes in contact with the immune system, which may form autoimmune antibodies against it) and altered antigen-presentation by non-professional antigen presenting cells.⁽²⁶⁻²⁸⁾

Table 1. Autoimmunity and immunological tolerance

Autoimmunity	
- Results from loss of autotolerance. - Has several mechanisms: <ol style="list-style-type: none"> 1. Genetic defects e.g. in HLA alleles and cellular self-antigens. 2. Loss of apoptotic stimuli causing increased proliferation of activated clones of autoreactive cells in the immune system. 3. Superantigen-related mechanisms causing increased proliferation of activated clones of autoreactive T cells in the immune system. 4. Antigen-related mechanisms: <ul style="list-style-type: none"> -Molecular mimicry (similarities between self-antigens and foreign antigens) -Cross-reaction (between self-antigens and foreign antigens) -Altered antigen presentation (causes a change in immunity against self-antigens) -Loss of sequestration (some antigens become in contact with the immune system e.g. eye lens) 	
Immunological tolerance	
(Protects against development of autoimmune diseases)	
A. Central tolerance	
1. In the thymus <ul style="list-style-type: none"> -Termed negative autoselection -Involves deletion of autoreactive T-cells -Occurs when T-cell receptors mistakenly bind to self-antigens and become autoreactive. 	

2. In the bone marrow

- Termed negative autoselection
- Involves deletion of autoreactive B-cells
- Occurs when immature B-cell receptors mistakenly bind to self-antigens and become autoreactive.

B. Peripheral tolerance

- Occurs outside the thymus and bone marrow
- Autoreactive cells become inactivated through several mechanisms as:
- Absence of appropriate MHC molecules
- Lack of co-stimulatory molecules
- Lack of T-cell help for B-cells activation
- Active suppression of autoreactive cells (mediated by T-cells).

Immunologic mechanisms of tissue damage in autoimmune diseases:

Immunological mechanisms beyond tissue damage occurring in autoimmune diseases include three different types of hypersensitivity reactions that are type II, III and IV. In type II hypersensitivity reactions that are called cytotoxic or cytolytic inflammatory reactions, autoantibodies (IgG or IgM) attack surface the antigens present on the outer surface of body cells causing cell lysis. Type II hypersensitivity reactions causes activation of the complement (a group of sequential proteins activated during immunological conditions) and opsonization (opsonin-enhanced phagocytosis by neutrophils, natural killer cells and macrophages). There is also antibody-mediated phagocytosis. Examples include Grave's disease, autoimmune hemolytic anemia, pernicious anemia (antibodies block the function of important proteins e.g. intrinsic factor necessary for vitamin B12 absorption), Goodpasture's disease, Idiopathic thrombocytopenic purpura, SLE, Hashimoto's thyroiditis, nephrotoxic nephritis and myasthenia gravis.^(13, 29)

In type III-induced autoimmunity (immune complex-mediated reactions), antigens and autoantibodies exist and escape from removal by the reticuloendothelial cells. This leads to complement activation, mast cell degranulation, histamine secretion and platelet aggregation (microthrombi formation). Examples of type III-induced autoimmunity include SLE and rheumatoid arthritis (RA). Treatment of type III-induced autoimmunity may include the excretion of autoantibodies

and immune complexes through plasmapheresis.^(1-4, 13)

In type IV-induced autoimmunity (delayed type hypersensitivity reactions), tissue damage occurs as a consequence of sensitized T lymphocyte activation leading to macrophage and lymphocytes activation with production of hydrolytic enzymes, reactive oxygen species, nitric oxide and cytokines e.g. tumor necrosis factor (TNF), interleukin-1 (IL-1) and IL-6. Insulin-dependent diabetes mellitus may belong to this category of diseases.^(13, 26)

Diagnosis of autoimmune diseases:

As there is a large number of autoantigens activating the own immune system resulting in the formation of autoantibodies by the non-tolerant self-reacting B cells, diagnosis of autoimmune diseases vary from disease to disease according to the organ involved and pathogenesis. However, there are common criteria for the laboratory diagnosis of autoimmune diseases, which include high serum immunoglobulins, high serum autoantibodies (e.g. anti-nuclear, anti-mitochondrial, anti-smooth muscle and rheumatoid factor in RA), high serum immune complexes, high serum tissue-specific autoantibodies (e.g. anti-thyroid antibodies), high serum soluble cytokine receptor (e.g. soluble IL-2R in RA) and low serum complement.^(1-4, 13)

Current treatment modalities for autoimmune diseases:

Current treatment for autoimmune diseases is directed towards treating the 3Cs (cause, condition and complications) with limited

success in some cases. Pharmacological treatment involves anti-inflammatory agents e.g. steroids⁽⁵⁾ and non-steroidal anti-inflammatory drugs to decrease the inflammatory reaction and to lower the production of inflammatory mediators upon immunological attack by the own immune system. Cytotoxic and immunosuppressive drugs may be helpful to decrease the activity of the immune cells e.g. methotrexate.⁽⁹⁾ Cytokine inhibitors e.g. anti-TNF may lower the pathological effects exerted by the excess pathological TNF cytokines.⁽³⁰⁾ Monoclonal antibodies are directed therapeutically to bind to inflammatory cytokines⁽³¹⁾ e.g. infliximab binds to TNF when treating RA.⁽³²⁾ However, therapeutic monoclonal antibodies are so expensive and carry numerous serious side effects.^(13, 34)

Al-hijamah (wet cupping therapy of prophetic medicine) clears blood from CPS

Histologically, ultrastructure of the skin (as evidenced by electron microscopic studies) is formed of three layers: epidermis, dermis and hypodermis (**Fig. 1A-B**). Epidermis is the outermost superficial layer that contains no blood capillaries. Uppermost layer of the epidermis is a layer of non-viable cells, the keratinized epithelium layer (stratum corneum = horny cell layer) that constitutes the skin barrier (having an average thickness of 10–20 µm) whose main function is to provide the primary barrier for the percutaneous absorption or excretion of substances and water across the skin. Underlying the stratum corneum is the viable epidermis (50–100 µm thick), that is responsible for the regeneration of the stratum corneum.⁽³⁵⁾

The dermis (1–2 mm thick) is the second cell layer of the skin that is directly adjacent to the epidermis and provides the mechanical support for the skin. The fenestrated skin capillaries lie at the dermo-epidermal junction.⁽³⁵⁾ Those superficial fenestrated capillary networks⁽³⁶⁻³⁸⁾ are suitable for the function of pressure-dependent filtration upon application of negative suction pressure as that done during Al-hijamah.

Practically, when performing Al-hijamah, skin scarifications (small superficial incisions, shartatmihjam in Arabic) done during Al-hijamah should be so superficial (about 0.1 mm in depth) just to open the skin barrier and

reach the superficial fenestrated dermal capillaries. No need to scarify the skin deeply during Al-hijamah in order not to damage the fenestrated dermal capillaries (causing loss of capillary fenestrations and filtration function) or cause unnecessary enormous bleeding.⁽³⁹⁾

The term wet cupping therapy (WCT) includes both Chinese (traditional) WCT and Al-hijamah (WCT of prophetic medicine). Al-hijamah has solid scientific and medical bases through clearing both the blood and interstitial fluids from CPS through a percutaneous pressure-dependent filtration of the blood passing through the fenestrated skin capillaries (**Fig. 1A-B**).⁽¹¹⁻¹²⁾ Traditional WCT has two main steps: scarification of the intact skin (not preceded by cupping) and suction using sucking cups applied to the skin surface i.e. double S technique. Al-hijamah has three main steps: 1st suction step using sucking cups applied to the intact skin (not preceded by a cupping step) to create skin upliftings, scarification of the skin uplifting (shartatmihjam) and a 2nd suction step i.e. triple S technique. This is immediately followed by pressure-dependent excretion of the CPS through the shartatmihjam according to the evidence-based Taibah mechanism (Taibah theory)⁽¹¹⁻¹²⁾ suggested recently by Salah M. El-Sayed. Taibah mechanism states that Al-hijamah is a minor surgical excretory therapeutic procedure than can clear both the interstitial spaces and blood partially from noxious substances causing the disease etiology or resulting during disease pathogenesis. This occurs through making use of the skin histological structure where the fenestrated skin capillaries may act as filters upon application of suction pressure produced inside the sucking cups during Al-hijamah.⁽¹¹⁻¹²⁾ This may facilitate regaining physiological homeostasis and recovery to variable extents depending on the degree of clearance of noxious substances, proper practice of Al-hijamah at relevant anatomical sites and on the other therapeutic benefits that can be gained during disease treatment using Al-hijamah.⁽¹²⁾ Scientific principles of Al-hijamah are similar to the principle of abscess evacuation where compression pressure on the abscess walls from outside evacuates pus (noxious substances in Al-hijamah) through the created abscess openings (represented by skin scarifications in Al-hijamah).⁽¹²⁾ Medical bases

of Al-hijamah are similar in principle to renal glomerular filtration where the pressure difference between the hydrostatic capillary pressure and Bowman's capsule (represented by the pressure difference between sucking cups and skin capillaries during Al-hijamah) helps pressure-dependent filtration of the skin blood capillaries. Al-hijamah is a three-step technique⁽⁴⁰⁻⁴¹⁾ (skin suction, scarification and suction), which includes all steps of both Chinese dry cupping therapy (a single suction step) and Chinese WCT (skin scarification

followed by suction).⁽¹¹⁻¹²⁾ CPS include both substances causing the disease process and substances resulting during disease pathogenesis.⁽¹¹⁻¹²⁾ CPS in autoimmune diseases include autoantibodies, antigen-antibody complexes, inflammatory mediators, prostaglandins, inflammatory cytokines, soluble cytokine receptors, hydrolytic enzymes, ROS and others (**Fig. 2**).⁽¹⁻⁴⁾

Figure 1A




Figure 1B




Figure 1. Electron microscopic structure of dermal vasculature.

A. Skin has a superficial network of fenestrated dermal capillaries.

B. Dermal fenestrated capillaries have pores that suit the function of pressure-dependent filtration during Al-hijamah.

Figure 2




Figure 2. Causative pathological substances (CPS) of autoimmune diseases are present in serum and interstitial fluids. CPS can be filtered through capillary pores then excreted out through the pressure-dependent effect of Al-hijamah.

The first and the last steps in Al-hijamah are sterilization of skin in a totally aseptic atmosphere. WCT of prophetic medicine (Al-hijamah) exerts three main functions in its three main steps: cupping (suction of skin inside cups) creates skin upliftings (skin dome) that collect interstitial fluid and filtered fluid containing CPS (**Fig. 3A-C**), puncturing (scarifying skin to excrete collected fluids) and cupping (second suction) introduces a negative pressure through the induced skin scarifications for filtration of capillary blood from CPS (**Fig. 4A-C**).⁽¹¹⁻¹²⁾ Cupped blood is the bloody excretion inside sucking cups that



Figure 3A. Skin uplifting (dome) created after putting sucking cup in the kahel region



Figure 3B. Skin uplifting (dome) created inside sucking cup put at local regions of pathology in the foot

Figure 3C




Figure 3. Wet cupping therapy of prophetic medicine (Al-hijamah) for treating autoimmune diseases.

A. First step in Al-hijamah is 1st suction step using sucking cups. Skin uplifting (dome) starts to form and progressively increases in size due to the viscoelastic nature of the skin under the effect of negative pressure suctioning.

B. A similar skin uplifting is created through putting sucking cups at the dorsum of the foot (local painful and inflammatory sites).

C. Boyle's law (pressure is inversely related to volume) is applied here. Collected fluids inside skin uplifting contain collected interstitial fluids with CPS (autoimmune antibodies, immune complexes, inflammatory mediators and cytokines).



Figure 4A. (Skin scarification = shartatmihjam in Arabic). **Criteria of shartatmihjam include:** Superficial longitudinal small incisions that must be confined to the skin upliftings and preceded by 1st suction step. Shartatmihjam should be superficial (0.1-0.2 mm in depth), short (1-2 mm in length), multiple and evenly distributed.

- Sucking cups should be applied immediately after scarifying the skin upliftings. Shartatmihjam is induced here in the dorsal surface of the kahel region (skin over the 7th cervical vertebra).



Figure 4B. (Skin scarification = shartatmihjam in Arabic). **(Skin scarifications of Al-hijamah = shartatmihjam in Arabic).** Shartatmihjam is done here at local anatomical areas at/ or very near to the site of pathology for the aim of better local tissue clearance.

- Skin scarifications should be confined to skin upliftings, superficial (0.1-0.2 mm in depth), short (1-2 mm in length), multiple and evenly distributed. Cups should be applied immediately after scarifying skin upliftings.

- Shartatmihjam is induced here in the dorsal surface of the foot region.

Figure 4C




Figure 4. Second step in Al-hijamah is shartatmihjam. Openings of the skin barrier through skin scarifications (shartatmihjam in Arabic) allow the excretion of the collected fluids containing CPS mixed with some blood due to scarification trauma. A. Shartatmihjam was created in the Kahel region. B. Shartatmihjam was created on the dorsuma of the foot region. C. detailed pressure-dependent excretion occurring through shartatmihjam.

Indeed, Al-hijamah is more comprehensive than traditional WCT and includes all steps and therapeutic benefits included in traditional WCT and treats all disease conditions treated by traditional WCT. Opposite is not true as traditional WCT is a partial form of Al-hijamah. We previously reported so many therapeutic benefits related to Al-hijamah and explained to what extent that is beneficial in treating so many different disease conditions.⁽⁴²⁾ This can be explained by knowing that Al-hijamah induces non-specific general blood clearance from noxious substances, immunological enhancement, pharmacological potentiation, analgesic effects, physiotherapy benefits, hemostatic benefits, hematological benefits, hemodynamic benefits, nutritional benefits and others as we previously discussed.⁽⁴²⁾ All those therapeutic benefits help the restoration of homeostasis and recovery from the disease condition. To our knowledge, there are no reported serious side effects, limitations or absolute contraindications related to the proper practice of Al-hijamah. Therapeutic indications of Al-hijamah were reported previously.⁽⁴²⁾ In other reports, non-specific blood clearance occurring during Al-hijamah was reported to clear venous blood from ferritin (ng/ml) by about 22%, from LDL-Cholesterol (mg/dl) by about 23%, from triglycerides (mg/dl) by about 27%, from cholesterol (mg/dl) by about 13.7% and from serum uric acid (mg/dl) by about 17%.⁽⁴³⁾ Blood samples were taken before Al-hijamah and ten days after it,⁽⁴³⁾ which measured the excretory and blood clearance benefits of Al-hijamah.⁽⁴³⁾ Recently, we suggested Al-hijamah as a novel promising treatment modality for iron overload conditions e.g. thalassemia.⁽⁴⁴⁾ Based on that, Al-hijamah can be regarded as an artificial excretory procedure that opens the skin barrier and enhances the natural excretory functions of the skin⁽¹¹⁻¹²⁾ as evidenced by the report that WCT enhanced the patients' natural immunity via increasing the number of natural killer (NK) cells and inducing leukocytosis.⁽⁴⁵⁾ The pressure-dependent filtration and excretion through Al-hijamah is similar in scientific principle to that occurring in the renal glomeruli and to that occurring during the pressure-dependent abscess evacuation where excretion of noxious CPS causes systemic blood clearance and restores physiological

homeostasis according to the evidence-based Taibah mechanism.⁽¹²⁾

Pressure-dependent excretion in Al-hijamah versus the renal glomeruli (table 2)

Largemolecules e.g. β -lipoprotein (Low density lipoproteins, LDL) cannot be filtered through the renal glomeruli, as their molecular weight (1,300,000) is too large to be filtered. Metabolism of LDL and other lipoproteins occur naturally inside the human body. However, excess pathological increase in LDL-cholesterol is a risk factor for the development of atherosclerosis and coronary heart diseases.⁽⁴³⁾ LDL binds to LDL receptor in the hepatocyte surface where an endocytosis process occurs resulting in the formation of endosomes. Then, the endosome fuses with a lysosome carrying hydrolytic lysosomal enzymes that hydrolyze the components of LDL-cholesterol into cholesterol esters, LDL proteins, and other lipids.⁽⁴⁶⁾ LDL was reported to be cleared percutaneously during Al-hijamah,⁽⁴³⁾ which confers therapeutic excretory functions to Al-hijamah that cannot be attained by physiological urinary excretion. However, other large molecules e.g. gamma globulins can pass through the skin capillaries into the interstitial fluid.⁽⁴⁷⁻⁴⁹⁾ Recently, serum IgE and IL-2 levels significantly decreased in patients having skin dermatoses after Al-hijamah, which confirms their excretion in the cupped blood.⁽⁵⁰⁾ Methodology described in this study was the triple S technique (Al-hijamah) not traditional WCT although the authors mistakenly described it as Chinese WCT.⁽⁵⁰⁾

In other words, WCT opens the skin barrier and enhances the natural excretory role of the skin. This may help in excreting abnormally increased gamma-globulins (e.g. rheumatoid factor), which was reported to be decreased significantly in serum of RA patients following Al-hijamah. Interestingly, large-sized macromolecules e.g. β -lipoproteins were reported to pass through the fenestrated pores of the skin capillaries out to the skin interstitial fluids,⁽⁴⁷⁻⁴⁹⁾ which may facilitate their excretion through Al-hijamah as evidenced by previous studies.^(11-12, 47-49)

Excretion through the renal glomeruli is limited to hydrophilic substances while excretion through Al-hijamah includes both hydrophilic and hydrophobic substances e.g.

cholesterol and triglycerides.⁽⁴³⁾ The excretory pressure gradient utilized during Al-hijamah (-150 - 430 mm Hg) is much higher than the net pressure gradient utilized for filtration at the renal glomeruli (10 mm Hg). Al-hijamah exerts a final excretion into the cupped blood while the glomerular filtrate has to undergo tubular reabsorption and secretion processes before final excretion. Excretion through the renal glomeruli is affected by particle charges of excreted substances and glomerular endothelium while excretion through Al-hijamah is not reported to be affected by that.⁽¹¹⁻¹²⁾

Recently, Al-hijamah was reported to benefit from the temporary compression

pressure exerted on the skin surface by the application of sucking cups for few minutes through the occurrence of reactive hyperemia phenomenon.⁽¹¹⁻¹²⁾ In reactive hyperemia, vascular compression causes a decrease in the blood supply to the skin for few minutes resulting in accumulation of vasodilator metabolites. As soon as vascular compression is removed, blood flow to the skin dramatically increases, which is called hyperemia.⁽⁵²⁾ This brings more blood to the skin circulation and enhances the clearance of blood from CPS. Moreover, WCT was reported to increase filtration at both capillary ends to clear blood from CPS to restore physiology and homeostasis⁽¹¹⁻¹²⁾ (Fig. 4-7).

Table 2. Differences between excretion through Al-hijamah and through renal excretion

	Al-hijamah (11-12, 42, 44, 50, 71)	Renal excretion
Excretion	Artificial and short in duration	Natural and continuous
Route	Percutaneous	Urinary
Mechanism	Pressure-dependent and size-dependent filtration through the fenestrated dermal capillaries followed by excretion	Pressure-dependent and size-dependent filtration through the fenestrated glomerular capillaries followed by excretion
Possibility of direct excretion	Possible e.g. excretion of urate crystals at gouty skin regions	Not (urine is processed through tubular reabsorption and secretion before final excretion)
Function	Non-specific biochemical clearance of blood and interstitial fluids. Many other therapeutic benefits	Hematopoietic, excretory and endocrine functions in the kidney
Excretion of hydrophobic substances e.g. cholesterol and triglycerides	occur	Not
Clearance	Blood clearance from both hydrophilic and hydrophobic noxious substances	Blood clearance from hydrophilic metabolic byproducts
Pressure gradient utilized for filtration	150 to 430 mmHg	10 mmHg
Excretory product	Bloody fluid (cupped bloody excretion) that contains mainly old damaged blood cells and CPS	Watery urine (variable in specific gravity and constituents)
Protein excretion	Present	Absent
Immunoglobulin (autoantibody) excretion	Reported	Absent
Excretion of inflammatory mediators	Reported	Absent

Volume of excretion	Variable and depends on pathology e.g. increases in hypertension and tissue edematous swellings	Variable and depends on water balance e.g. increases in hydration states and decreases in dehydration
Shartatmihjam (induced skin scarifications)	Present	Absent
Charge carried by excreted particles e.g. -ve charges in albumin	Does not affect excretion	Affect
Excretion of soluble antigens, soluble cytokine receptor and antigen-antibody complexes	Reported	Not done
Role in regulation of acid-base balance	Less important	Vital (via excretion of various concentrations of titratable acids)
Other therapeutic benefits	Analgesia, physiotherapy, homeostasis and tissue-protective benefits	Hematopoietic, acid-base balance and homeostatic benefits
Role of Al-hijamah	Better clearance of blood and interstitial fluids in healthy subjects	Renal patients benefit from Al-hijamah in improving the defective clearance functions and relieving side effects of hemodialysis.
Other names	Cupping therapy of prophetic medicine, triple S technique	Urine formation and micturition




Figure 5. Third step in Al-hijamah is ^{2nd} suction using sucking cups. Excreted cupped blood carries the filtrate mixed with some old hemolyzed and fragmented blood cells. A. Cupped blood excreted at Kahel and Akhdayin regions. B. Cupped blood excreted at local foot region. C. Pressure-dependent excretion of a serous plasma-like fluid.



Local honey may be put for proper fixation of sucking cups

Sucking cups put at akhdayin regions (postero-inferior to ear lobules)

Figure 6A



Figure 6B

Figure 6. Third step in Al-hijamah is ^{2nd} suction using sucking cups.

Excreted cupped blood carries the filtrate mixed with some old hemolyzed and fragmented blood cells.

A. Cupped blood excreted at Kahel and Akhdayin regions.

B. Cupped blood excreted at local foot region.

C. Pressure-dependent excretion of a serous plasma-like fluid.



Figure 6C

Al-hijamah-induced serum filtration. Continuous suction inside sucking cups causes pressure-dependent filtration then excretion of a serous plasma-like fluid.


Fig. 7

Figure 7. Restoration of physiology and homeostasis. This occurs after pressure-dependent excretion of CPS of autoimmune diseases during Al-hijamah

Al-hijamah as a reported promising treatment for rheumatoid arthritis

In Arabic countries, the scientific terms WCT, blood cupping therapy and bloodletting cupping therapy refer to the triple S technique (Al-hijamah) not the double S technique (traditional WCT) as Al-hijamah is an inherited modality of treatment since the era of prophetic medicine in the Arabic medical literature. Recently, bloodletting cupping therapy was reported to successfully treat autoimmune diseases e.g. RA where the pain of RA was maximally reduced.⁽⁴⁵⁾ Interestingly, CPS of RA e.g. rheumatoid factor (RF) and soluble interleukin-2 receptors (SIL-2R) were reduced significantly in patients' venous blood after Al-hijamah, which gave the conclusion that those CPS were excreted in the cupped blood during the pressure-mediated filtration in WCT (Al-hijamah). Interestingly, Al-hijamah was reported to increase the number of NK cells.⁽⁴⁵⁾ NK cells are a subset of effector lymphocytes that, in contrast to T cells, do not require prior sensitization with antigen for their immunological function. The lytic functions of NK cells are regulated by a set of inhibitory receptors (killer inhibitory receptors)

recognizing MHC class I determinants on target cells.^(1-4, 13) Recently, traditional WCT (partial form of Al-hijamah) was reported to clear blood from pain-mediating substances e.g. substance P, which may explain partially the analgesic and antinociceptive effects of Al-hijamah.⁽⁵⁴⁾

Excretion of RF, SIL-2R and other CPS of RA through Al-hijamah⁽⁴⁵⁾ constitutes a non-specific serum clearance in those patients that is so beneficial and paves the way for facilitating the therapeutic benefits exerted by pharmacological treatments. When a significant serum clearance is achieved, pharmacological treatments will be directed towards a lower concentration of CPS, which will be easier to manage pharmacologically. Excretion of disease CPS may be better than treating those CPS or abolishing their pathologic effects while they are present inside the human body.⁽⁵⁵⁻⁵⁶⁾

Lessons gained from treating RA with Al-hijamah

An interesting single study was done in Al-Azhar university in Cairo, Egypt⁽⁴⁵⁾ that evaluated the improvements in rheumatoid

patients treated using a combination of Al-hijamah with conventional pharmacological treatments revealed marked significant improvements in all the tested clinical parameters during the three successive months that followed Al-hijamah in a time-dependent manner. Clinical improvements were progressively increasing month after month. Best improvements were recorded in the 3rd month after performing Al-hijamah (table 3). Visual analog scale (VAS) for measuring pain intensity was reported to decrease by about 59% in the combined treatment group versus 20% in the conventional pharmacological treatment group. Tender joint count (TJC) decreased by about 76% in the combined treatment group versus 34% in the conventional treatment group. Swollen joint count (SJC) decreased by about 78% in the combined treatment group versus 18% in the conventional treatment group. Disease-activity score (DAS) decreased by about 33% in the combined treatment group versus 4% in the conventional treatment group.⁽⁴⁵⁾

As for the laboratory parameters that measured RA activity, there was also a significant improvement in all the tested parameters. SIL-2R (pg/ml) decreased by about 11.55% in the combined treatment group versus 0.64% in the conventional treatment group. Concentration of SIL-2R was reported to correlate with disease activity, clinical deterioration and increased patients suffering.⁽⁴⁵⁾

Erythrocyte sedimentation rate (ESR) (mm/hour) decreased by about 17% in the combined treatment group versus 2.3% in the conventional treatment group. C-reactive protein (CRP) (mg/dl) decreased by about 79.3% in the combined treatment group versus 11.4% in the conventional treatment group. RF (IU/ml) decreased by about 85.54% in the combined treatment group versus 29.75% in the conventional treatment group.⁽⁴⁵⁾

As for the laboratory parameters measuring the natural immunity, there was a significant improvement in all the tested parameters. Physiological leukocytosis was evident where leukocytes count ($\times 10^9$) increased by about 44.81% in the combined treatment group versus a decrease of about 3.6% (leucopenia) in the conventional treatment group. Percentage of NK cells (NK Cell %) increased by about 33.29% in the

combined treatment group versus 1.17% in the conventional treatment group.⁽⁴⁵⁾ Based on that, Al-hijamah enhanced the natural innate immunity and suppressed the pathological immunity (autoantibodies, inflammatory cytokines production and immune pathology-related inflammatory reactions).

As for the pharmacological potentiation effects, they measured the percentage ratio of therapeutic effects of a combination of Al-hijamah with conventional treatment (e.g. for RA) versus the conventional treatment group (i.e. % improvement after combined treatment / % improvement after conventional treatment). All the measured parameters of pharmacological potentiation were significant. Using the values in table 3, calculated therapeutic beneficial effects improved after combined treatment (versus conventional treatment only) by 2.95 folds for VAS, by 2.235 folds for TJC, by 4.333 folds for SJC, by 8.25 folds for DAS, by 18.04 folds for SIL-2R, by 7.39 folds for ESR, 6.95 folds for CRP, by 2.87 folds for RF, by 12.44 folds for percentage increase in leucocytes (leukocytosis) and by 28.45 folds for percentage increase in NK cells.⁽⁴⁵⁾ This confirms the evidence-based Taibah mechanism (Taibah theory for scientific mechanisms and rationale of Al-hijamah)⁽¹¹⁻¹²⁾ where Al-hijamah exerts synergistic effects with pharmacological treatments when treating RA.⁽⁴⁵⁾ As Al-hijamah is a mechanical (not a pharmacological) line of treatment, no chemical interaction or pharmacological antagonism will occur when combining Al-hijamah with pharmacological treatments.

However, for further future research studies, it will be better to specify a separate study group to investigate the pure therapeutic effect of Al-hijamah only, which may help in quantitating to what extent is the participation of Al-hijamah as a sole treatment in relieving patients with RA. It is important to mention some technical details during reporting the therapeutic results of Al-hijamah e.g. the best anatomical sites for putting sucking cups for treating RA and the possible therapeutic rationale beyond selecting the joint anatomical sites and the remote anatomical sites. Interestingly, we recently reported the therapeutic rationale beyond selecting local and general anatomical sites for treating many diseases including RA.⁽⁵⁷⁾ Briefly, as we had learnt from prophetic medicine, putting sucking

cups at the affected joint sites clears the interstitial fluids of the selected areas from disease CPS while putting sucking cups at the remote anatomical sites from the site of pathology e.g. in the back of the trunk and the back of the neck clears better the serum from CPS.⁽⁵⁷⁾ Cumulative clearance of both serum and interstitial fluids (through excretion of noxious substances partially or totally) may help improving disease pathophysiology, restore physiological homeostasis (Fig. 7), and terminate or ameliorate disease pathogenesis which may be reflected positively upon improving the clinical outcome. Putting sucking cups at sites of pathology (e.g. inflammation) helps to clear those sites from substances causing the pathology (e.g. inflammatory mediators).

Moreover, the authors were not successful when they did not estimate the laboratory parameters in the first few hours after Al-hijamah to report on the pure excretory benefit that occurred due to Al-hijamah-induced blood and interstitial fluid clearance.

The improvement that occurred in the clinical condition of RA patients was secondary to the subsidence of the autoimmunity and inflammatory reactions secondary to the decrease in serum parameters of the noxious substances and the physiological increases in serum parameters of WBCs and NK cells. The improvement that was reached in the 3rd month after Al-hijamah is due to the combinatory effect of CPS excretion (immediate therapeutic benefit after Al-hijamah), immunity enhancement (gradually increasing therapeutic benefit) and subsidence of pathology (secondary therapeutic benefit to blood clearance and immunomodulation).

Therapeutic importance of clearing ferritin in autoimmune diseases using Al-hijamah

Ferritin is the circulating iron storage protein that is regarded also as an acute phase reactant marker exhibiting high levels in different inflammatory conditions. Hyperferritinemia was reported in SLE patients, diabetic patients, multiple sclerosis patients, and RA patients. Hyperferritinemia is a marker of disease activity in SLE patients.⁽⁵⁸⁾ Compared to subjects with normal ferritin levels, a significantly greater proportion of patients with hyperferritinemia had thrombocytopenia, lupus anticoagulant and

anti-cardiolipin antibodies, which may suggest that hyperferritinemia may be an early marker in secondary antiphospholipid syndrome in SLE patients.⁽⁵⁹⁾

Elevation of serum ferritin was documented in patients with juvenile RA and was helpful in monitoring the response to therapy.⁽⁶⁰⁾ Ferritin may have a role in the pathogenesis of autoimmune diseases e.g. the antiphospholipid syndrome. Hyperferritinemia was reported to be correlated with the antiphospholipid syndrome, its catastrophic variant and the presence of anti-CMV antibodies among those patients.⁽⁶¹⁾ Moreover, hyperferritinemia ($\geq 1,250 \mu\text{g/L}$) was reported to rule out some autoimmune diseases and hematologic diseases⁽⁶²⁾ where increased serum ferritin and reduced activity of iron-regulatory proteins were reported to indicate monocyte iron accumulation, which may be important for the pathophysiology of anemia of chronic diseases in humans.⁽⁶³⁾ Moreover, increased serum iron and ferritin constitute the hallmark of iron overload conditions as thalassemia, sideroblastic anemia and hemochromatosis.^(42, 44)

Furthermore, hyperferritinemia ($\geq 2,500 \mu\text{g/L}$) was reported to be associated with the relapsing-progressive type of multiple sclerosis,⁽⁶⁴⁾ adult-onset Still's disease,⁽⁶⁵⁾ primary and secondary hemophagocytic lymphohistiocytosis.⁽⁶⁶⁻⁶⁷⁾ Interestingly, low serum ferritin was reported to be associated with a good response to therapy in patients with autoimmune disease-associated hemophagocytic syndrome⁽⁶⁶⁻⁶⁷⁾ that usually presents with hyperferritinemia ($> 500 \mu\text{g/L}$), high fever, hepatosplenomegaly, lymphadenopathy, central nervous system involvement and disseminated intravascular coagulation.⁽⁶⁸⁾

Based on that, significant clearance of serum ferritin in patients having autoimmune diseases using Al-hijamah is so beneficial in correcting the pathogenesis in such patients and in restoring physiological homeostasis (Fig. 7).

Al-hijamah versus phlebotomy and plasmapheresis Therapeutic benefits and improvements reported after Al-hijamah were better than those reported after phlebotomy⁽⁶⁹⁻⁷¹⁾ where Al-hijamah improved much better the arterial O_2 saturation and respiration when treating smoking in patients having chronic

obstructive pulmonary diseases without causing significant blood loss.⁽⁶⁹⁾ Al-hijamah was reported to do better than phlebotomy in decreasing CRP dramatically and improving the ESR in patients having chronic urticaria and angioedema.⁽⁷⁰⁾ Methodology described in those studies was the triple S technique (Al-hijamah) not traditional WCT. Detailed differences between Al-hijamah and phlebotomy were previously reported.^(44, 71)

Autoimmune diseases (including RA) exhibit a similar abnormality in blood chemistry as in RA i.e. they have high serum level of autoimmune antibodies and immune complexes (**tables 3-4**). Plasmapheresis (plasma exchange transfusion) is used for treating some autoimmune diseases to clear blood plasma from autoimmune antibodies.⁽⁷²⁻⁷⁴⁾ Plasmapheresis aims at removing immune mediators as autoantibodies, immune complexes, and proinflammatory substances e.g. complement components and coagulation factors.⁽⁷²⁻⁷⁴⁾ Diseases treated by plasmapheresis include Goodpasture's disease

(in which antglomerular basement membrane antibodies are present), SLE, myasthenia gravis and Guillain-Barre syndrome. Plasmapheresis is an expensive, risky, sophisticated, time-consuming (1-3 hours) excretory treatment that needs a special plasmapheresis machine. Preparatory steps for plasmapheresis include assessing hematological indices and plasma volume. Steps of plasmapheresis include separating plasma from blood cells and discarding plasma. Replacement fluid should be given to patients, which may include albumin, electrolyte solutions, hydroxy-ethyl starch, and fresh frozen plasma or purified protein products such as individual clotting factors or antithrombin III.⁽⁷²⁻⁷⁴⁾ Massive sudden removal of antibodies during plasmapheresis may lead to a rebound increase in the production of autoantibodies.⁽⁷⁴⁾ So, plasmapheresis should be done under the umbrella of immunosuppressive therapy to decrease the possibility of rebound increase in autoantibodies⁽⁷⁵⁻⁷⁶⁾ (**table 5**).

Table 3. Therapeutic improvements after Al-hijamah in treating RA reported by Sahbaa et al.⁽⁴⁵⁾

	Before Al-hijamah	3 Months after conventional treatment only	3 Months after combined conventional treatments + Al-hijamah
<u>Clinical parameters</u>			
Visual analog score (VAS)	7.80±0.28	6.25±1.33	3.20 ±1.54
Tender joint count (TJC)	19.53±0.95	12.8±54.01	4.73 ±2.76
Swollen joint count (SJC)	15.83±0.97	12.95±3.66	3.56 ±1.99
Disease-activity score (DAS)	6.15±0.10	5.92±0.61	4.10 ±0.69
<u>Laboratory parameters</u>			
Soluble interleukin-2 receptors SIL-2R (pg/ml)	2023±508.46	2007±525.57	1789.34
ESR (mm/hr)	44±13.90	42.95±4.49	36.46±3.35
CRP (mg/dl)	46.40±5.45	41.10±22.74	9.60±1.90
RF (IU/ml)	131.47±23.89	92.36±15.12	19.01±3.49
<u>Immunological parameters</u>			
WBCs(1 x10 ⁹)	6.94±0.28	6.69±1.76	10.05±1.50
NK Cell%	8.50 ±0.46	8.60 ±0.85	11.33 ±0.47

Table 4. Possible therapeutic role of Al-hijamah in treating different autoimmune diseases

N.B. Autoimmune diseases have common criteria that are presence of autoantibodies and inflammatory mediators

Autoimmune Disease	Characterized by presence of: (4)	Possible therapeutic role of Al-hijamah (11-12, 42, 44, 50, 71)
Systemic Lupus erythematosus	Immune complexes in serum and in the basement membrane of glomeruli, skin, endothelium, synovia of joints and kidney • Anti-double stranded DNA and anti-leukocyte antibodies • Anti-phospholipid antibody (also termed, "lupus anti-coagulant") • Polyclonal B-cell activation	<ul style="list-style-type: none"> • Excretion of autoimmune antibodies, cytokines and immune complexes • Enhancement of natural immunity e.g. activation of natural killer cells • Pharmacological potentiation
Rheumatoid Arthritis	• High serum soluble cytokine receptors (SIL-2 R) • High serum rheumatoid factors—IgM (or IgG/IgA) to the Fc of IgG. • Association with Epstein Barr virus and human T lymphocyte virus-1	<ul style="list-style-type: none"> • Excretion of autoimmune antibodies, cytokines, rheumatoid factor, soluble cytokine receptors and immune complexes • Enhancement of natural immunity e.g. activation of natural killer cells • Pharmacological potentiation
Hashimoto's thyroiditis	•Anti-thyroglobulin and anti-microsomal antibodies	<ul style="list-style-type: none"> • Excretion of autoimmune antibodies, cytokines and immune complexes • Enhancement of natural immunity e.g. activation of natural killer cells • Pharmacological potentiation
Multiple Sclerosis	•Antibodies to the myelin basic protein secondary to cell death • Oliogoclonal (not polyclonal antibodies) in cerebral spinal fluid	<ul style="list-style-type: none"> • Excretion of autoimmune antibodies, cytokines and immune complexes • Enhancement of natural immunity e.g. activation of natural killer cells. • Pharmacological potentiation
Scleroderma	•Some autoantibodies e.g. anti-centromere antibodies and anti-Scl-70 antibodies	<ul style="list-style-type: none"> • Excretion of autoimmune antibodies, cytokines and immune complexes • Enhancement of natural immunity e.g. activation of natural killer cells. • Pharmacological potentiation
Goodpasture's Syndrome	<ul style="list-style-type: none"> • Anti-glomerular basement membrane antibodies • Shared antigens between the lung (alveolar) and the glomerular basement membrane • Linear deposition of IgG and complement 	<ul style="list-style-type: none"> • Excretion of autoimmune antibodies, cytokines and immune complexes • Enhancement of natural immunity e.g. activation of natural killer cells. • Pharmacological potentiation

Addison's Disease	<ul style="list-style-type: none"> • Antibodies to adrenal cell microsomes 	<ul style="list-style-type: none"> • Excretion of autoimmune antibodies, cytokines and immune complexes • Enhancement of natural immunity e.g. activation of natural killer cells. • Pharmacological potentiation
Insulin-dependent Diabetes Mellitus	<ul style="list-style-type: none"> • Antibodies to glutamic acid decarboxylase 	<ul style="list-style-type: none"> • Excretion of autoimmune antibodies, cytokines and immune complexes • Enhancement of natural immunity e.g. activation of natural killer cells. • Pharmacological potentiation
Pernicious Anemia	<ul style="list-style-type: none"> • Antibodies bind cell surface antigens and destroy parietal cells. • Antibodies bind to gastric cells that secrete intrinsic factor. • Antibodies bind to intrinsic factor and prevent binding of vitamin B12 	<ul style="list-style-type: none"> • Excretion of autoimmune antibodies, cytokines and immune complexes • Enhancement of natural immunity e.g. activation of natural killer cells. • Pharmacological potentiation
Grave's Disease	<ul style="list-style-type: none"> • Stimulatory antibodies mimic actions of ligand (thyroxin stimulating hormone) • Get uncontrolled secretion of thyroxin which leads to hyperthyroidism 	<ul style="list-style-type: none"> • Excretion of autoimmune antibodies, cytokines and immune complexes • Enhancement of natural immunity e.g. activation of natural killer cells. • Pharmacological potentiation
Myasthenia Gravis	<ul style="list-style-type: none"> • Antibodies are inhibitory and block acetylcholine binding 	<ul style="list-style-type: none"> • Excretion of autoimmune antibodies, cytokines and immune complexes • Enhancement of natural immunity e.g. activation of natural killer cells. • Pharmacological potentiation
Ankylosing Spondylitis	<p>Prior infection with Klebsiellapneumoniae</p> <ul style="list-style-type: none"> • There is no rheumatoid factor 	<ul style="list-style-type: none"> • Excretion of autoimmune antibodies, cytokines and immune complexes • Enhancement of natural immunity e.g. activation of natural killer cells. • Pharmacological potentiation
AcanthosisNigricans	<ul style="list-style-type: none"> • Antibodies to the insulin receptor that block binding of insulin to the insulin receptor 	<ul style="list-style-type: none"> • Excretion of autoimmune antibodies, cytokines and immune complexes • Enhancement of natural immunity e.g. activation of natural killer cells. • Pharmacological potentiation
Cold Agglutinin	Antibodies that agglutinate blood	<ul style="list-style-type: none"> • Excretion of autoimmune

Disease	cells below 37°C	antibodies, cytokines and immune complexes <ul style="list-style-type: none"> • Enhancement of natural immunity e.g. activation of natural killer cells. • Pharmacological potentiation
----------------	------------------	---

As for Al-hijamah, it may have some advantages over plasmapheresis in clearing blood from the offending CPS without the need for the sophisticated plasma exchange transfusion (therapeutic plasma exchange) (**table 5**). During the first step in Al-hijamah, collected interstitial fluids with CPS, filtered fluids (from blood capillaries containing CPS) and hemolyzed blood cells accumulate inside the skin upliftings (domes) induced during suction steps of Al-hijamah. No intact blood cells (RBCs, WBCs and platelets) exist in this fluid mixture. Blood cells have diameters in microns that are about 100-1000 times larger than the pores of the skin capillaries (6-100 nm in diameter) and are therefore too big to pass through the pores of the skin capillaries⁽¹¹⁻¹²⁾ and cannot be filtered. Puncturing skin upliftings and applying second suction step excrete collected fluids beneath the skin barrier. Superficial scarifications open the skin barrier (1st layer of epidermis) and transmit the suction pressure to the superficial fenestrated skin capillaries to make them act as filters for exerting a pressure-dependent filtration and excretion of the small sized noxious substances circulating in the fenestrated subepidermal capillaries. Superficial nature of the skin scarifications is quite important to ensure that there is no damage to the superficial skin capillaries. However, inevitable minor trauma may occur to the capillaries at some scarification points and cause the excretion to be bloody.^(42, 44, 71) Superficial skin scarifications (shartatmihjam in Arabic) represent proper practice of Al-hijamah while deep skin scarifications may injure deeper blood vessels and represent a malpractice that may cause significant bleeding.

Al-hijamah is a pressure-dependent filtration procedure that is done through the fenestrated skin capillaries using suction pressure created inside suction cups. Reported sucking pressure (from -200 to -560 hecta Pascal, equivalent to -150 to - 420 mmHg) was

reported to be created inside the sucking cups during WCT.⁽⁷⁸⁾ This suction pressure (filtration force) is transmitted (through skin scarifications = shartatmihjam induced during WCT) to around the skin capillaries to be added to the capillary hydrostatic pressure (-33 mmHg at the arterial end of capillaries and -13 mmHg at the venous ends of capillaries)^(11-12, 78) that drives fluids to the outside of the fenestrated skin capillaries against the capillary osmotic pressure (+ 20 mmHg)^(11-12, 78) that drives fluids to the inside of the skin capillaries.

By mathematical calculation of pressure differences, a pressure gradient and a traction force across the skin and capillaries are created leading to increased filtration at the arterial end of capillaries at net pressure of -163 to -433 mmHg and at the venous end of capillaries at net pressure of -143 to -413 mmHg^(11-12, 77-78) resulting in clearance of blood from fluids containing CPS of autoimmune diseases (autoantibodies, immune complexes and inflammatory cytokines) (tables 2, 5).

Moreover, pharmacological potentiation induced by WCT to current treatment modalities in treating autoimmune diseases was proven.^(42, 44-45) This can be explained on the basis that WCT excretes CPS and facilitates the therapeutic roles exerted by the conventional pharmacological therapeutics. Interestingly, Al-hijamah is a highly recommended treatment in prophetic medicine where Prophet Muhammad peace be upon him said: "Cure is in three: in sharatmihjam, gulp of honey and cauterization. I do not recommend my nation to cauterize".⁽⁷⁹⁾

Al-hijamah for treating other autoimmune diseases

Compared with RA, other autoimmune diseases may have a similar pathogenesis and blood chemistry to some extent in which CPS may include autoantibodies, immune complexes, inflammatory mediators, cytokines,

products of autoreactive immune cells and others (**tables 3-5**). Al-hijamah-induced non-specific blood clearance from disease CPS, activation of natural immunity, pharmacological potentiation, analgesic effect and other therapeutic benefits^(11-12, 42) may be promising in treating such diseases. Based on that, Al-hijamah may be a promising treatment for autoimmune diseases through its serum and local interstitial fluid clearance effect from CPS. Autoimmune antibodies that are present in serum of autoimmune patients were reported to be excreted outside the human body

through Al-hijamah,⁽⁴⁵⁾ which may be beneficial in inhibiting the progression steps of pathogenesis of autoimmune diseases and in potentiating the therapeutic effects of current pharmacological treatments.

In conclusion, Al-hijamah may be promising in treating different autoimmune diseases (**Table 6**) as a sole treatment or adjuvant treatment to current treatment modalities. Al-hijamah may be superior to plasmapheresis (plasma exchange transfusion (**72-73, 81-83**)) in many points when treating autoimmune diseases (**Tables 4-6**).

Table 5. Differences between Al-hijamah and plasmapheresis (therapeutic plasma exchange)

	Plasmapheresis (72-74, 81-83)	Wet cupping therapy (Al-hijamah) (11-12, 42, 44, 71)
Definition	Hematological procedure for separating blood cells from plasma through a specific plasmapheresis machine	Percutaneous excretory procedure for excreting CPS from plasma and interstitial fluids
Scientific principle	To discard autoantibodies from plasma	Pressure-dependent excretion of offending substances in plasma and interstitial fluids.
Criteria	Sophisticated, risky to some extent and expensive	Simple, safe and economic
Value	Excretes autoantibodies from plasma	Excretes CPS (autoantibodies, immune complexes, cytokines and inflammatory mediators) from plasma and interstitial fluids
Where can it be done?	In hematology departments in hospitals	Outpatient clinic
Repeatability	May be repeated (higher risks)	Easily repeatable (no risk or harm)
Indications	For therapeutic indications as in autoimmune diseases e.g. Goodpasture's syndrome, myasthenia gravis, Guillain-Barre syndrome and SLE.	Preventive and therapeutic for a wide range of diseases e.g. autoimmune diseases and others.
Steps	Assessing hematological indices and plasma volume, separating plasma from blood cells, returning blood cells and a plasma substitute to patient.	Demarcation of skin points, sterilization, suction of skin inside cups, scarifications, 2nd suction and sterilization
Duration	1-3 hours	About 30 minutes
Route	Venous line	Percutaneous
Before the procedure	Control bleeding tendency, assess blood volume and volume of plasma to be excreted	Control bleeding tendency
Complications	Bleeding, protein loss	Reversible skin mark

Other benefits	None	Confer many immunological and pharmacological potentiation benefits ⁽⁴²⁾
Contraindication	Bleeding tendency	No contraindication (hemophilia should be controlled first)
For treating rheumatoid arthritis	Not indicated	Proved to be beneficial in decreasing pain, excreting rheumatoid factor, excreting SIL-2R and increasing the count of natural killer cells in patients' sera
Needs prior calculation of blood volume and plasma volume	Essential	No
Excretion of antibodies present in plasma	Sudden massive and may lead to rebound increase in production of autoantibodies. Should be done under the umbrella of cytotoxic drugs.	Gradual not causing rebound. Repeatability of AI-hijamah may benefit patients. More gradual excretion of all CPS including autoantibodies.
Necessity for replacement fluids	Necessary. Replacement fluids during plasma exchange include albumin, electrolyte solutions, hydroxy-ethyl starch, fresh frozen plasma, or purified protein products such as individual clotting factors or antithrombin III.	No need
Blood cells separation from plasma	A must. Done inside plasmapheresis machine	Not done. Filtered part of plasma containing CPS is excreted out during the process (no machine is used)
Needs simultaneous immunosuppressive therapy	Essential to avoid rebound increase in producing autoantibodies	No
Treat coexisting diseases	No	Yes e.g. hypertension and hyperlipidemia
Other names	Therapeutic plasma exchange	Prophetic method of WCT (AI-hijamah), triple S technique.

Table 6. Therapeutic benefits of AI-hijamah for patients having autoimmune diseases

- 1. Enhances the natural immunity** (through inducing physiological leukocytosis, natural killer cell lymphocytosis⁽⁴⁵⁾, enhances production of immune stimulatory cytokines and suppresses production of immune inhibitory cytokines)⁽⁸⁴⁾
- 2. Suppresses the abnormal pathological immunity through serum clearance from causative pathological substances:**
 - Suppresses the autoimmune reactions through excreting circulating autoantibodies (e.g. rheumatoid factor in rheumatoid arthritis).⁽⁴⁵⁾
 - Suppresses the autoimmune reactions through excreting the antigen-antibody complexes.
 - Suppresses the autoimmune reactions through excreting the related inflammatory mediators (e.g. soluble interleukin-2 receptors in rheumatoid arthritis).⁽⁴⁵⁾
- 3. Suppresses the autoimmune reactions through clearing serum from ferritin (marker for autoimmune diseases)(43).**

N.B. Pathological roles of ferritin in autoimmune diseases include:⁽⁵⁸⁻⁶²⁾

.Marker of disease activity in SLE.

.Reported to increase in SLE, diabetes mellitus, multiple sclerosis, juvenile RA

and catastrophic variant of antiphospholipid syndrome.

. Involved in the pathogenesis of chronic anemia in autoimmune diseases.

.Lowering serum ferritin is associated with a good response to treatment.

4. Exerts potent analgesic effects via several mechanisms e.g. serum clearance from pain-mediating substances as substance P.⁽⁵⁴⁾

5. Potentiates therapeutic effects of pharmacological treatments.⁽⁴⁵⁾

5. Minimizes drug-induced side effects e.g. Al-hijamah-induced physiological leukocytosis counteracts methotrexate-induced leucopenia.⁽⁴⁵⁾

6. Al-hijamah may treat associated medical conditions and reduce the required dose and frequency of drug administration.⁽⁴²⁾

7. Al-hijamah may treat associated diseases and clears serum significantly from LDL-cholesterol, triglycerides and total cholesterol (may guard against premature atherosclerosis).⁽⁴²⁻⁴³⁾

Acknowledgements

We are so grateful to the library of Sohag faculty of medicine, Sohag University, Egypt for providing the internet facility and helpful textbooks.

Conflict of interest

The authors declare that there is no conflict of interest.

References:

1. Tan EM. Autoantibodies, autoimmune disease, and the birth of immune diagnostics. J Clin Invest. 2012 Nov 1; 122(11):3835-6.
2. Maurice R.G. O'Gorman, Albert D. Donnenberg, Handbook of human immunology. 2nd edition, 2008. P 371
3. LESLEY-JANE EALES (2003). Immunology for Life Scientists. John Wiley & Sons Ltd, The Atrium, Southern Gate, Chichester, West Sussex PO19 8SQ, England
4. Reginald Gorczynski, Jacqueline Stanley. Clinical Immunology. (1999). Landes Bioscience, 810 S. Church Street, Georgetown, Texas, U.S.A. 78626
5. Ghazale A, Chari ST. Optimising corticosteroid treatment for autoimmune pancreatitis. Gut. 2007 Dec;56(12):1650-2.
6. Halilova KI, Brown EE, Morgan SL, Bridges SL Jr, Hwang MH, et al. (2012) Markers of treatment response to methotrexate in rheumatoid arthritis: where do we stand? Int J Rheumatol 2012: 978396.
7. Isik M, Halacli B, Atmaca O, Etg  S, Do    an I, et al. (2013) Triple DMARD combination for rheumatoid arthritis resistant to methotrexate and steroid combination: a single-center experience. RheumatolInt 33: 1425-1427.
8. Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, Gromnica-Ihle E, Kellner H, Krause A, Schneider M, S  rensen H, Zeidler H, Thriene W, Sieper J. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet. 2002 Apr 6; 359(9313):1187-93.
9. Ranganathan P, Eisen S, Yokoyama WM, McLeod HL (2003) Will pharmacogenetics allow better prediction of methotrexate toxicity and efficacy in patients with rheumatoid arthritis? Ann Rheum Dis 62: 4-9.
10. Wu HY. Induction of mucosal tolerance in SLE: a sniff or a sip away from ameliorating lupus? Clin Immunol. 2009; 130(2):111-22.
11. El Sayed SM, Mahmoud HS and Nabo MMH. Methods of Wet Cupping Therapy (Al-Hijamah): In Light of Modern Medicine and Prophetic Medicine. AlternInteg Med 2013, 2:3
12. El Sayed SM, Mahmoud HS and Nabo MMH. Medical and scientific bases of Wet Cupping Therapy (Al-Hijamah): In Light of Modern Medicine and Prophetic Medicine. AlternInteg Med 2013, 2:5.

13. Abla M. EL-Mishad. (2011). Manual of Medical Microbiology & Immunology Part 1.
14. Ashour HM, Seif TM. The role of B cells in the induction of peripheral T cell tolerance. *J Leukoc Biol.* 2007 Nov; 82(5):1033-9.
15. Proal AD, Albert PJ, Marshall TG. The human microbiome and autoimmunity. *Curr Opin Rheumatol.* 2013 Mar; 25(2):234-40. doi: 10.1097/BOR.0b013e32835cedbf.
16. Vojdani A. A Potential Link between Environmental Triggers and Autoimmunity. *Autoimmune Dis.* 2014; 2014:437231. doi: 10.1155/2014/437231. Epub 2014 Feb 12.
17. Bolon B. Cellular and molecular mechanisms of autoimmune disease. *Toxicol Pathol.* 2012; 40(2):216-29.
18. Molina V, Shoenfeld Y. Infection, vaccines and other environmental triggers of autoimmunity. *Autoimmunity.* 2005; 38(3):235-45.
19. Bellone M. Autoimmune Disease: Pathogenesis. *ENCYCLOPEDIA OF LIFE SCIENCES* 2005
20. Carrilho FM. Etiopathogenesis of autoimmune thyroiditis. *Acta Med Port.* 1989 Aug-Oct; 2(4-5):231-3.
21. Fujinami RS, von Herrath MG, Christen U, Whitton JL. Molecular mimicry, bystander activation, or viral persistence: infections and autoimmune disease. *Clin Microbiol Rev.* 2006 Jan; 19(1):80-94.
22. Verbsky JW, Chatila TA. Immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) and IPEX-related disorders: an evolving web of heritable autoimmune diseases. *Curr Opin Pediatr.* 2013 Dec; 25(6):708-14. doi: 10.1097/MOP
23. Ayensu WK, Tchounwou PB, McMurray RW. Molecular and cellular mechanisms associated with autoimmune diseases. *Int J Environ Res Public Health.* 2004 Mar; 1(1):39-73.
24. Yasutomo K. Pathological lymphocyte activation by defective clearance of self-ligands in systemic lupus erythematosus. *Rheumatology (Oxford).* 2003 Feb; 42(2):214-22.
25. Wucherpfennig KW. Mechanisms for the induction of autoimmunity by infectious agents. *J Clin Invest.* 2001 Oct; 108(8):1097-104.
26. Burmester G, Bezutto A. (2003). Color atlas of immunology. Gramlich, Pliezhausen, Germany
27. De Bernardo E, Davies TF. Antigen-specific B-cell function in human autoimmune thyroiditis. *J Clin Immunol.* 1983; 3(4):392-8.
28. Markel G, Mussaffi H, Ling KL, Salio M, Gadola S, Steuer G, Blau H, Achdout H, de Miguel M, Gonen-Gross T, Hanna J, Arnon TI, Qimron U, Volovitz I, Eisenbach L, Blumberg RS, Porgador A, Cerundolo V, Mandelboim O. The mechanisms controlling NK cell autoreactivity in TAP2-deficient patients. *Blood.* 2004 Mar 1; 103(5):1770-8.
29. Rosen A, Casciola-Rosen L. Altered autoantigen structure in Sjögren's syndrome: implications for the pathogenesis of autoimmune tissue damage. *Crit Rev Oral Biol Med.* 2004 Jun 4; 15(3):156-64.
30. Edwards CK 3rd, Green JS, Volk HD, Schiff M, Kotzin BL, et al. (2012) Combined anti-tumor necrosis factor- α therapy and DMARD therapy in rheumatoid arthritis patients reduces inflammatory gene expression in whole blood compared to DMARD therapy alone. *Front Immunol* 3: 366.
31. Lee S, Ballow M. Monoclonal antibodies and fusion proteins and their complications: targeting B cells in autoimmune diseases. *J Allergy Clin Immunol.* 2010 Apr; 125(4):814-20. doi: 10.1016/j.jaci.2010.02.025.
32. Ortea I, Roschitzki B, Ovalles JG, Longo JL, de la Torre I, et al. (2012) Discovery of serum proteomic biomarkers for prediction of response to infliximab (a monoclonal anti-TNF antibody) treatment in rheumatoid arthritis: an exploratory analysis. *J Proteomics* 77: 372-382.
33. Caporali R, Pallavicini FB, Filippini M, Gorla R, Marchesoni A, Favalli EG, Sarzi-Puttini P, Atzeni F, Montecucco C. Treatment of rheumatoid arthritis with anti-TNF-alpha agents: a reappraisal. *Autoimmun Rev.* 2009 Jan; 8(3):274-80. doi: 10.1016/j.autrev.2008.11.003.

34. Chandrashekara S. The treatment strategies of autoimmune disease may need a different approach from conventional protocol: a review. *Indian J Pharmacol.* 2012 Nov-Dec; 44(6):665-71.
35. Bouwstra JA, Honeywell-Nguyen PL, Gooris GS, Ponc M. Structure of the skin barrier and its modulation by vesicular formulations. *Prog Lipid Res.* 2003 Jan; 42(1): 1-36. Review.
36. Kanitakis J. Anatomy, histology and immunohistochemistry of normal human skin. *Eur J Dermatol.* 2002; 12: 390-9.
37. Takada M, Hattori S. Presence of fenestrated capillaries in the skin. *Anat Rec.* 1972 Jun; 173(2):213-9.
38. Daróczy J, Hüttner I. Fenestrated capillaries in the rat paw dermis adjacent to epidermis and skin appendages. *Z Mikrosk Anat Forsch.* 1978; 92(3):598-606.
39. Malik IA, Akhter S, Kamal MA. Treatment of psoriasis by using Hijamah: A case report. *Saudi Journal of Biological Sciences* (2015) 22, 117–121
40. ErrasS, Bemjilali L, Essaoudouni L. Wet-cupping in the treatment of recalcitrant and oral genital ulceration of Behcet disease: A randomized controlled trial. *Indian journal of traditional knowledge.* 2013 Mar; 12(4):613-615.
41. Ahmadi A, Schwebel DC, Rezaei M. The efficacy of wet-cupping in the treatment of tension and migraine headache. *Am J Chin Med.* 2008; 36(1):37-44.
42. El Sayed SM, Al-quliti A, Mahmoud HS, Baghdadi H, Maria RA, Nabo MMH and Hefny A. Therapeutic benefits of Al-hijamah: in light of modern medicine and prophetic medicine. *Ajmr* 2(2):46-71
43. ALSHOWAFI FK. Effect of Blood Cupping on Some Biochemical Parameter. *Med. J. Cairo Univ.*, 2010; 78(1): 311-315
44. El Sayed SM, Abou-Taleb A, HBaghdadi H, Mahmoud HS, Maria RA, Ahmed NS, Nabo MM Percutaneous excretion of iron and ferritin (through Al-hijamah) as a novel treatment for iron overload in beta-thalassemia major, hemochromatosis and sideroblastic anemia. *Med Hypothes* 2013, 83:238-46.
45. Ahmed SM, Madbouly NH, Maklad SS, Abu-Shady EA. Immunomodulatory effects of bloodletting cupping therapy in patients with rheumatoid arthritis. *Egypt J Immunol.* 2005; 12(2):39-51.
46. Goldstein JL, Brown MS, Anderson RG, Russell DW, Schneider WJ. Receptor-mediated endocytosis: concepts emerging from the LDL receptor system. *Annu Rev Cell Biol.* 1985;1:1-39.
47. Asscher A W, Henry Jones J. (1965) Capillary permeability to plasma proteins. *Postgrad. Med. J.* 41, 425- 434.
48. Courtice FC. (1961): The transfer of proteins and lipids from plasma to lymph in the leg of the normal and hypercholesterolaemic rabbit, *J. Physiol. (Lond.)*, 155, 456.
49. Courtice FC. and Morris B. (1955): The exchange of lipids between plasma and lymph of animals, *Quart. J. exp. Physiol.*, 40, 138.49. El-Domyati M, Saleh F, Barakat M and Mohamed N. Evaluation of Cupping Therapy in Some Dermatoses. *Egyptian Dermatology Online Journal.* 2013; 9: 79-82.
50. El-Domyati M, Saleh F, Barakat M and Mohamed N. Evaluation of Cupping Therapy in Some Dermatoses. *Egyptian Dermatology Online Journal.* 2013; 9: 79-82.
51. Braschi S, Neville TA, Vohl MC, Sparks DL. Apolipoprotein A-I charge and conformation regulate the clearance of reconstituted high density lipoprotein in vivo. *J Lipid Res.* 1999 Mar; 40(3):522-32.
52. Saladin KS. *Anatomy & Physiology: The Unity of Form and Function.* In: *The microcirculation and the lymphatic system* (3rd edition), 2003. The McGraw-Hill companies 262.
53. O'Gorman Maurice, Donnemberg Albert. *Handbook of human immunology.* 2nd edition. Taylor & Francis Group 2008. P164.
54. Tian H , Tian YJ, Wang B, Yang L, Wang YY, Yang JS. Impacts of bleeding and cupping therapy on serum P substance in patients of postherpetic neuralgia. *Zhongguo Zhen Jiu.* 2013 Aug; 33(8): 678-81.
55. Fernández-Real JM, Peñarroja G, Castro A, García-Bragado F, Hernández-Aguado I, Ricart W. Bloodletting in high-ferritin type 2 diabetes: effects on insulin sensitivity and beta-cell function. *Diabetes.* 2002 Apr; 51(4):1000-4.

56. Genuis SJ, Curtis L, Birkholz D. Gastrointestinal Elimination of Perfluorinated Compounds Using Cholestyramine and Chlorella pyrenoidosa. *ISRN Toxicol.* 2013 Sep 9; 2013:657849. doi: 10.1155/2013/657849. eCollection 2013.
57. Mahmoud HS, Abou-El-Naga M, Omar NA, El-Ghazzawy HA, Fathy YM and Nabo MMH, .El Sayed SM. Anatomical Sites for Practicing Wet Cupping Therapy (Al-Hijamah): In Light of Modern Medicine and Prophetic Medicine. *AlternInteg Med* 2013. In press.
58. Orbach H, Zandman-Goddard G, Amital H, Barak V, Szekanecz Z, Szucs G, Danko K, Nagy E, Csepány T, Carvalho JF, Doria A, Shoenfeld Y. Novel biomarkers in autoimmune diseases: prolactin, ferritin, vitamin D, and TPA levels in autoimmune diseases. *Ann N Y Acad Sci.* 2007 Aug; 1109:385-400.
59. Zandman-Goddard G, Orbach H, Agmon-Levin N, Boaz M, Amital H, Szekanecz Z, Szucs G, Rovinsky J, Kiss E, Corocher N, Doria A, Stojanovich L, Ingegnoli F, Meroni PL, Rozman B, Gomez-Arbesu J, Blank M, Shoenfeld Y. Hyperferritinemia is associated with serologic antiphospholipid syndrome in SLE patients. *Clin Rev Allergy Immunol.* 2013 Feb; 44(1):23-30. doi: 10.1007/s12016-011-8264-0.
60. Sreedharan A, Bowyer S, Wallace CA, Robertson MJ, Schmidt K, Woolfrey AE, Nelson RP Jr. Macrophage activation syndrome and other systemic inflammatory conditions after BMT. *Bone Marrow Transplant.* 2006 Apr; 37(7):629-34.
61. Agmon-Levin N, Rosário C, Katz BS, Zandman-Goddard G, Meroni P, CerveraR, Stojanovich L, Blank M, Pierangeli S, Praprotnik S, Meis Ed, Seguro LP, Ruffatti A, Pengo V, Tincani A, Doria A, Shoenfeld Y. Ferritin in the antiphospholipid syndrome and its catastrophic variant (cAPS). *Lupus.* 2013 Nov; 22(13):1327-35.
62. Lian F, Wang Y, Yang X, Xu H, Liang L. Clinical features and hyperferritinemia diagnostic cutoff points for AOSD based on ROC curve: a Chinese experience. *Rheumatol Int.* 2012 Jan; 32(1):189-92. doi: 10.1007/s00296-010-1601-4. Epub 2010 Aug 27.
63. Theur I, Mattle V, Seifert M, Mariani M, Marth C, Weiss G. Dysregulated monocyte iron homeostasis and erythropoietin formation in patients with anemia of chronic disease. *Blood.* 2006 May 15; 107(10):4142-8.
64. Da Costa R, Szyper-Kravitz M, Szekanecz Z, Csépany T, Dankó K, Shapira Y, Zandman-Goddard G, Orbach H, Agmon-Levin N, Shoenfeld Y. Ferritin and prolactin levels in multiple sclerosis. *Isr Med Assoc J.* 2011 Feb; 13(2):91-5.
65. Cornet AD, Thielen N, Kramer MH, Nanayakkara PW, KooterAJ. Adult-onset Still's disease and haemophagocytic syndrome. *Ned Tijdschr Geneesk.* 2010; 154:A2528.
66. Breda L1, Nozzi M, De Sanctis S, ChiarelliF. Laboratory tests in the diagnosis and follow-up of pediatric rheumatic diseases: an update. *Semin Arthritis Rheum.* 2010 Aug; 40(1):53-72.
67. Tabata R, Tabata C, Terada M, Nagai T. Hemophagocytic syndrome in elderly patients with underlying autoimmune diseases. *Clin Rheumatol.* 2009 Apr; 28(4):461-4. doi: 10.1007/s10067-009-1086-2.
68. Sun XH, Zheng WJ, Zhang W, Zhao Y. A clinical analysis of hemophagocytic syndrome in autoimmune diseases]. *Zhonghua Nei Ke Za Zhi.* 2010 Oct; 49(10):836-40.
69. Hekmatpou D, Moeini L, Haji-Nadali S. The effectiveness of wet cupping vs. venesection on arterial O2 saturation level of cigarette smokers: A randomized controlled clinical trial. *Pak J Med Sci.* 2013 Nov -Dec; 29(6): 1349 -1353.
70. Sharifi MS, AfrasiAbian H. Evaluation of wet cupping treatment in patients with chronic urticaria and angioedema. *The Open Conference Proceedings Journal,* 2013, 3, 1 -5
71. El Sayed SM, Baghdadi H, Abou-Taleb A, Mahmoud HS, Maria RA, Ahmed NS, Nabo MM. Al-hijamah and oral honey for treating thalassemia and conditions of iron overload and hyperferremia: toward improving the therapeutic outcomes. *J blood Med.* In press

72. Charles D, Jeremy PB. Plasmapheresis in Immunologic Renal Disease. *Blood Purif* 2012; 33:190–198.
73. McLeod BC. Therapeutic apheresis: use of human serum albumin, fresh frozen plasma and cryosupernatant plasma in therapeutic plasma exchange. *Best Pract Res ClinHaematol*. 2006; 19(1):157-67.
74. Heininger K, Gibbels E, Besinger UA, Borberg H, Hartung HP, Grabensee B, Toyka KV. Role of therapeutic plasmapheresis in chronic inflammatory demyelinating polyneuropathy. *ProgClinBiol Res*. 1990; 337:275-81.
75. Dau PC. Immunologic rebound. *J ClinApher*. 1995; 10(4):210-7.
76. Hans R, Sharma RR, Marwaha N. Dramatic response to plasma exchange in systemic lupus erythematosus with acute complications: Report of two cases. *S Indian J Crit Care Med*. 2013 Nov; 17(6):385-7. doi: 10.4103/0972-5229.123462.
77. Sarin H (2010) Physiologic upper limits of pore size of different blood capillary types and another perspective on the dual pore theory of microvascular permeability. *J Angiogenes Res* 2: 14.
78. Huber R, Emerich M, Braeunig M (2011) Cupping-is it reproducible? Experiments about factors determining the vacuum. *Complement Ther Med* 19: 78-83.
79. Al-Bukhari MI. The English Translation of Sahih Al Bukhari. Book of medicine. Chapter of (Cure is in three). Hadeeth numbers 5680 -5681. Assryia library, Sayda, Lebanon 2002.
80. Russi G, Marson P. Urgent plasma exchange: how, where and when. *Blood Transfus*. 2011 Oct; 9(4):356-61.
81. Jacob CK. Plasmapheresis--principles and practice. *J Indian Med Assoc*. 2001 Jul; 99(7):364-7.
82. Winters JL. Plasma exchange: concepts, mechanisms, and an overview of the American Society for Apheresis guidelines. *Hematology Am SocHematolEduc Program*. 2012; 2012:7-12.
83. Valbonesi M, Montani F, Florio G, Zerbi D, Beltramelli A. Plasmapheresis combined with lymphocytapheresis and cytotoxic drugs as a therapeutic modality in neuroimmunological diseases. *Ital J Neurol Sci*. 1984 Mar; 5(1):35-40.
84. Zhang CQ, Liang TJ, Zhang W. Effects of drug cupping therapy on immune function in chronic asthmatic bronchitis patients during protracted period. *ZhongguoZhong Xi Yi*